The FDA approved a new schizophrenia drug, Cobenfy, offering a unique treatment approach. This drug targets a different receptor than traditional antipsychotics. Schizophrenia is a severe mental illness affecting 1% of Americans. Bristol-Myers Squibb Company granted the approval.